Assignee: UCB Pharma S.A.

Location: Brussels, BE
No. of patents: 44

Number	Title	Issue Date
8168634	Thiazole derivatives as kinase inhibitors A series of thiazole derivatives which are substituted in the 2-position by a substituted morpholin-4-yl moiety, being selective inhibitors of P13 kinase enzymes, are accordingly of benefit in medicine, for example in the treatment of inflammatory, autoimmune, cardi...	05/01/2012
8129505	Comb polymers The present invention provides a process for producing a comb polymer comprising the steps of: a) providing: (i) (w+z) molar equivalents of a monomer; (ii) one molar equivalent of an initiator compound of formula (IX), wherein B3 represents a halogen, B	03/06/2012
8093238	Fused thiazole derivatives as kinase inhibitors A series of 5,5-dimethyl-5,6-dihydro-1,3-benzothiazol-7(4H)-one and 7,7-dimethyl-5,6,7,8-tetrahydro-4H-[1,3]thiazolo[5,4-c]azepin-4-one derivatives, and analogues thereof, which are substituted in the 2-position by an optionally substituted benzofused morpholin-4-yl...	01/10/2012
8075889	Antibody molecules having specificity for human IL-6 The invention relates to antibody molecules having specificity for antigenic determinants of IL-6, therapeutic uses of the antibody molecules and methods for producing said antibody molecules. ...	12/13/2011
8071582	Substituted aniline derivatives The present invention relates to novel aniline derivatives and their use in therapy, in particular their use in the treatment of fungal infections. ...	12/06/2011
8067005	Divalent antibody fragments Divalent antibody fragments are described, each of which has one or more interchain bridges containing a synthetic or naturally occurring polymer selected from a polyalkylene, polyakenylene, polyoxyalkylene or polysaccharide. Each bridge may be the residue of a homo...	11/29/2011
8062865	Expression control using antibody expression optimisation sequences The present invention provides a dicistronic message for producing an antibody molecule, in which the upstream cistron contains DNA coding for the light chain of the antibody and the downstream cistron contains DNA coding for the corresponding heavy chain, character...	11/22/2011
8057794	Antibody molecules which bind to human IL-17 The invention relates to antibody molecules having specificity for antigenic determinants of IL-17, therapeutic uses of the antibody molecules and methods for producing said antibody molecules. ...	11/15/2011
8053564	Cross-linked antibodies The present invention provides a compound consisting essentially of the following elements: one or more reactive groups; and two or more cross-linked antibodies or fragments thereof; characterised in that the or each reactive group is suitable for attaching an effec...	11/08/2011
8053562	Modified antibody fragments The present invention relates to a new class of modified antibody fragments. The present invention provides an antibody fragment to which one or more effector molecules is attached characterized in that the native interchain disulphide bond between the heavy (CHI) a...	11/08/2011
7993864	Assay for identifying antibody producing cells The present invention provides a homogeneous assay for identifying an antibody producing cell producing an antibody which binds to a selected antigen comprising: a) providing a population of antibody producing cells; b) incubating said population of antibody produci...	08/09/2011
7977464	Antibody molecules specific to human tumour necrosis factor alpha There is disclosed antibody molecules containing at least one CDR derived from a mouse monoclonal antibody having specificity for human TNFα. There is also disclosed a CDR grafted antibody wherein at least one of the CDRs is a hybrid CDR. Further disclosed are DNA ...	07/12/2011
7943605	Compounds comprising a lactam or a lactam derivative moiety, processes for making them, and their uses The present invention relates to compounds of formula (I) comprising a lactam or a lactam derivative moiety, processes for preparing them, pharmaceutical compositions comprising said compounds and their uses as pharmaceuticals. ...	05/17/2011
7931900	Method for the treatment of multiple sclerosis by inhibiting IL-17 activity The present invention provides a method for the treatment and/or prophylaxis of multiple sclerosis (MS) comprising administering a therapeutically effective amount of an inhibitor of IL-17 activity. ...	04/26/2011
7919606	Biological products There is disclosed antibody molecules containing at least one CDR derived from a mouse monoclonal antibody having specificity for human CD22. There is also disclosed a CDR grafted antibody wherein at least one of the CDRs is a modified CDR. Further disclosed are DNA...	04/05/2011
7910618	Albumin-binding conjugates comprising a fatty acid and PEG The present invention provides an albumin-binding compound essentially of the following elements: a spacer group, a water-soluble bridging group, a fatty acid chain and an acidic group characterised in that the acidic group is attached to the distal end of the fatty...	03/22/2011
7888344	Fused thiazole derivatives as kinase inhibitors A series of 5,6-dihydro-1,3-benzothiazol-7(4H)-one derivatives, and analogues thereof, which are substituted in the 2-position by an optionally substituted morpholin-4-yl moiety, being selective inhibitors of PD kinase enzymes, are accordingly of benefit in medicine...	02/15/2011
7872106	Sclerostin-binding antibodies Compositions and methods relating to epitopes of sclerostin protein, and sclerostin binding agents, such as antibodies capable of binding to sclerostin, are provided. ...	01/18/2011
7863316	Extended release formulation of Levetiracetam The present invention relates to extended release pharmaceutical compositions of Levetiracetam and processes for preparing the same. The extended release tablet of Levetiracetam is with a core comprising of Levetiracetam and water dispersible rate controlling polyme...	01/04/2011
7858122	Extended release formulation of levetiracetam An extended release pharmaceutical composition of Levetiracetam with once a day dosage regime and the process of preparing it. The extended release tablet of Levetiracetam is with the core comprising of Levetiracetam and water dispersible rate controlling polymer, a...	12/28/2010
7842787	Biological products There are disclosed antibody molecules containing at least on CDR derived from a mouse monoclonal antibody having specificity for human KDR. There is also disclosed a CDR grafted antibody wherein at least one of the CDRs is a hybrid CDR. Further disclosed are DNA se...	11/30/2010
7795256	Thieno-pyridinone derivatives as kinase inhibitors A series of thieno[2,3-b]pyridin-6(7H)-one derivatives, substituted in the 3-position by an arylcarbonyl or heteroaryl-carbonyl moiety, being inhibitors of p38 MAP kinase, are accordingly of use in medicine, for example in the treatment and/or prevention of immune o...	09/14/2010
7790414	Methods for producing antibodies The invention relates to a method of obtaining an antibody with a desired function, the method comprising: a) bringing a population of B cells into contact with a capturing agent; b) separating the captured B cells from the uncaptured B cells; c) culturing a plurali...	09/07/2010
7786177	Phenylalanine enamide derivatives Phenylalanine enamide derivatives of formula (1) are described: wherein R1 is a group Ar1 L2Ar2Alk- in which: Ar1 is...	08/31/2010
7763729	Bicyclic heteroaromatic derivatives Bicyclic heteroaromatic derivatives of formula (1) are described: F(1) where: the dashed line joining A and C(Ra) is present and represents a bond and A is a —N═ atom or a —C(Rb)═ group, or the dashed line is absent and A is a —N(R	07/27/2010
7754447	Methods for producing recombinant proteins The present invention provides a method for controlling the partitioning of a recombinant protein between the supernatant and the periplasm in E. coli host cell cultures wherein expression of the recombinant protein by said cells is under the control of an in...	07/13/2010
7745156	Methods for diagnosis and treatment of epithelial-derived cancers The present invention relates to the use of a polypeptide (CD27L) for diagnosis of epithelial-related cancers, in particular kidney cancer e.g. renal cell cancer and colorectal cancer, e.g. colon cancers, as well as in methods of treatment of such cancers. ...	06/29/2010
7736635	Branched molecular scaffolds for linking polymer residues to biologically active moieties Branched molecular scaffolds are provided which are capable of linking two polymer residues (derived, for example, from polyethylene glycol) to two, three or four residues derived from biologically active molecules (e.g. from whole antibodies or from functionally ac...	06/15/2010
7678785	Substituted aniline derivatives The present invention relates to novel aniline derivatives and their use in therapy, in particular their use in the treatment of fungal infections. ...	03/16/2010
7662609	host cells with modified PhoS/PstS periplasmic phosphate-binding proteins, and method of manufacturing recombinant fabs The present invention provides an Ecoli host cell expressing a recombinant antibody characterized in that the Ecoli host cell has been genetically modified in order to change at least one physical property of one or more Ecoli proteins which in ...	02/16/2010
7645770	Phenylalanine enamide derivatives Phenylalanine enamide derivatives of formula (1) are described: wherein R1 is a group Ar1L2Ar2Alk- in which: Ar1	01/12/2010
7638630	2,6-quinolinyl and 2,6-naphthyl derivatives, processes for preparing them and their uses as VLA-4 inhibitors The present invention concerns 2,6-quinolinyl and 2,6-naphthyl derivatives of formula (I), processes for preparing them, pharmaceutical compositions containing them and their use as pharmaceuticals for the treatment of VLA-4 dependent inflammatory diseases such as f...	12/29/2009
7629474	Process for preparing 2-oxo-1-pyrrolidine derivatives The present invention relates to a new process for preparing 2-oxo-I-pyrrolidine derivatives of general formula (I) wherein the substituents are as defined in the specification. ...	12/08/2009
7608694	Antibody molecules having specificity for human IL-1β The invention relates to an antibody molecule having specificity for antigenic determinants of IL-1β, therapeutic uses of the antibody molecule and methods for producing said antibody molecule. ...	10/27/2009
7601817	Antibody peg positional isomers, compositions comprising same, and use thereof The present invention relates to recombinant protein PEG positional isomers. More specifically, it relates to PEG positional isomers of an antibody having specificity for antigenic determinants of human tumor necrosis factor alpha (TNFα). More specifically, it rela...	10/13/2009
7592455	Bicyclic heteroaromatic compounds as kinase inhibitors A series of 5-6 fused ring bicyclic heteroaromatic derivatives, based in particular on the 6-oxo-6,7-dihydrothieno[2,3-b]pyridine ring system, being inhibitors of p38 kinase, are accordingly of use in medicine, for example in the treatment and/or prevention of immun...	09/22/2009
7521460	Thienopyridone derivatives as kinase inhibitors A series of thieno[2,3-b]pyridin-6(7H)-one derivatives, substituted in the 2-position by a carbonyl- or sulfonyl-linked pyrrolidin-1-yl or related moiety, being inhibitors of p38 MAP kinase, are accordingly of use in medicine, for example in the treatment and/or pre...	04/21/2009
7456286	Bicyclic heteroaromatic compounds as kinase inhibitors A series of 5-6 fused ring bicyclic heteroaromatic derivatives, based in particular on the 5-oxo-4,5-dihydro-1H-pyrrolo[3,2-b]pyridine ring system, being inhibitors of p38 kinase, are accordingly of use in medicine, for example in the treatment and/or prevention of ...	11/25/2008
7452976	Biological products There are disclosed antibody molecules containing at least one CDR derived from a mouse monoclonal antibody having specificity for human KDR. There is also disclosed a CDR grafted antibody wherein at least one of the CDRs is a hybrid CDR. Further disclosed are DNA s...	11/18/2008
7402662	Antibody molecules specific to human tumor necrosis factor alpha There is disclosed antibody molecules containing at least one CDR derived from a mouse monoclonal antibody having specificity for human TNFα. There is also disclosed a CDR grafted antibody wherein at least one of the CDRs is a hybrid CDR. Further disclosed are DNA ...	07/22/2008

«First «Previous1 2 Next»Last»

PatentStorm

Did You Know...

PatentStorm News

Assignee: UCB Pharma S.A.